SOLVO Scientific Publications

Reviews

1. Utilization of membrane vesicle preparations to study drug-ABC transporter interactions.
   Glavinas H, Méhn D, Jani M, Oosterhuis B, Herédi-Szabó K, Krajcsi P
   Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):721-32.



2. The role of ABC transporters in drug resistance, metabolism and toxicity.
   Glavinas H, Krajcsi P, Cserepes J, Sarkadi B
   Curr Drug Deliv. 2004 Jan;1(1):27-42. Review.



3. Ins and outs of the ABCG2 multidrug transporter: An update on in vitro functional assays
   Csilla Hegedűs, Gergely Szakács, László Homolya, Tamás I. Orbán, Ágnes Telbisz, Márton Jani and Balázs Sarkadi
   Advanced Drug Delivery Reviews 61: 47-56 (2009)

Role of transporters in drug ADME

1. Leflunomide and A771726, its metabolite are high affinity substrates of BCRP - implications for drug resistance.
   Kis E, Nagy T, Jani M, Molnár E, Jánossy J, Ujhelly O, Német K, Herédi-Szabó K, Krajcsi P
   Ann Rheum Dis. 2008 Apr 8. [Epub ahead of print]



2. Characterization of 5(6)-carboxy-2,'7'-dichlorofluorescein transport by MRP2 and utilization of this substrate as a fluorescent surrogate for LTC4.
   Heredi-Szabo K, Kis E, Molnar E, Gyorfi A, Krajcsi P
   J Biomol Screen. 2008 Apr;13(4):295-301. Epub 2008 Mar 18.



3. [In vitro methods suitable for the prediction of drug and ABC transporter, especially ABCG2 interactions]
   Pál A, Kis E, Méhn D, Glavinas H, Nagy T, Mészáros P, Báthori G, Krajcsi P, Falkay G
   Acta Pharm Hung. 2007;77(4):205-16. Hungarian.



4. Modulation of sinusoidal and canalicular elimination of bilirubin-glucuronides by rifampicin and other cholestatic drugs in a sandwich culture of rat hepatocytes.
   Lengyel G, Veres Z, Tugyi R, Vereczkey L, Molnár T, Glavinas H, Krajcsi P, Jemnitz K.
   Hepatol Res. 2008 Mar;38(3):300-9. Epub 2007 Aug 29.



5. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions.
   Glavinas H, Kis E, Pál A, Kovács R, Jani M, Vági E, Molnár E, Bánsághi S, Kele Z, Janáki T, Báthori G, von Richter O, Koomen GJ, Krajcsi P
   Drug Metab Dispos. 2007 Sep;35(9):1533-42. Epub 2007 May 30.



6. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2.
   Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, Glavinas H, Janáki T, von Richter O, Báthori G, Szente L, Krajcsi P
   J Pharmacol Exp Ther. 2007 Jun;321(3):1085-94. Epub 2007 Mar 8.



7. Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp).
   Schmitt U, Abou El-Ela A, Guo LJ, Glavinas H, Krajcsi P, Baron JM, Tillmann C, Hiemke C, Langguth P, Härtter S
   J Neural Transm. 2006 Jul;113(7):787-801. Epub 2005 Oct 27.

Role of transporters in nutrition, bioavailability and in risk assessement of environmental toxicants

1. Mechanistic study on the intestinal absorption and disposition of baicalein.
   Zhang L, Lin G, Kovács B, Jani M, Krajcsi P, Zuo Z
   Eur J Pharm Sci. 2007 Jul;31(3-4):221-31. Epub 2007 Apr 9.



2. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2).
   Williamson G, Aeberli I, Miguet L, Zhang Z, Sanchez MB, Crespy V, Barron D, Needs P, Kroon PA, Glavinas H, Krajcsi P, Grigorov M
   Drug Metab Dispos. 2007 Aug;35(8):1262-8. Epub 2007 May 3.



3. Specific interactions of chloroacetanilide herbicides with human ABC transporter proteins.
   Oosterhuis B, Vukman K, Vági E, Glavinas H, Jablonkai I, Krajcsi P
   Toxicology. 2008 Jun 3;248(1):45-51. Epub 2008 Mar 14.



4. Interaction of ivermectin with multidrug resistance proteins (MRP1, 2 and 3).
   Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M
   Chem Biol Interact. 2006 Feb 25;159(3):169-79. Epub 2005 Dec 27.

Miscellaneous

1. Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization.
   Cserepes J, Szentpetery Z, Seres L, Ozvegy-Laczka C, Langmann T, Schmitz G, Glavinas H, Klein I, Homolya L, Varadi A, Sarkadi B, Elkind NB
   Biochem Biophys Res Commun. 2004 Jul 30;320(3):860-7.



2. Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties.
   Fantin M, Quintieri L, Kúsz E, Kis E, Glavinas H, Floreani M, Padrini R, Duda E, Vizler C
   Eur J Pharmacol. 2006 Mar 27;535(1-3):301-9.